ORIGINAL ARTICLES

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

M Hofmann¹, O Stoss², T Gaiser¹, H Kneitz¹, P Heinmöller², T Gutjahr³, M Kaufmann³, T Henkel² and J Rüschoff¹

¹ Institute of Pathology and Biomedical Research, Klinikum Kassel GmbH, Kassel, Germany
² TARGOS Molecular Pathology GmbH, Kassel, Germany
³ F Hoffmann-La Roche Ltd, Basel, Switzerland

Correspondence to:
Professor J Rüschoff, Institute of Pathology, Nordhessen, Germany; rueschoff{at}patho-nordhessen.de

Aims: To investigate the correlation between centrally assessed human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) results and response to treatment of patients with metastatic breast cancer enrolled in a first-line, phase II, open-label, 3-weekly trastuzumab (Herceptin) monotherapy trial (WO16229).

Methods: Samples from participants in the WO16229 trial were collected and tumour HER2 status determined by IHC and FISH. HER2 test results were interpreted according to manufacturers’ test kit protocols. Responders were defined as patients showing either partial or complete responses.

Results: Response data were available for 103/105 patients; centrally confirmed HER2 status was available for 95 patients. Intra-laboratory concordance for central IHC and FISH results was 93%. Complete responses were seen in two patients; their samples were IHC 3+ and FISH positive. Partial responses were seen in 17 patients; all were IHC 3+ and 14 were FISH positive. IHC and FISH showed 100% and 84.2% sensitivity, respectively, in determining response to trastuzumab. Polysomy was observed in 27% of patients; six responded to trastuzumab treatment. All six responders showed HER2 overexpression (IHC 3+) and HER2 gene amplification; two were FISH negative due to chromosome 17 polysomy.

Conclusions: HER2 determination by IHC and FISH correlates with clinical response data in the WO16229 trial with high concordance of IHC and FISH results. Polysomy is the major cause of response in FISH-negative cases; polysomic cases should be retested by strictly standardised IHC.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Sauter, G., Lee, J., Bartlett, J. M.S., Slamon, D. J., Press, M. F. (2009). Reply to V. Arena et al. JCO 27: e9-e10 [Full Text]  
• Brunelli, M., Manfrin, E., Martignoni, G., Miller, K., Remo, A., Reghellin, D., Bersani, S., Gobbo, S., Eccher, A., Chilosi, M., Bonetti, F. (2009). Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria. Am J Clin Pathol 131: 678-682 [Abstract] [Full Text]  
• Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
• Yeh, C.-H., Whitmire, W. A. III, Albitar, M. (2008). Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer. Clin. Chem. 54: 1831-1839 [Abstract] [Full Text]  
• Vanden Bempt, I., Van Loo, P., Drijkoningen, M., Neven, P., Smeets, A., Christiaens, M.-R., Paridaens, R., De Wolf-Peeters, C. (2008). Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing. JCO 26: 4869-4874 [Abstract] [Full Text]  
• Rosenberg, C. L. (2008). Polysomy 17 and HER-2 Amplification: True, True, and Unrelated. JCO 26: 4856-4858 [Full Text]  
• Nunes, C B, Rocha, R M, Reis-Filho, J S, Lambros, M B, Rocha, G F S, Sanches, F S F, Oliveira, F N, Gobbi, H (2008). Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol. 61: 934-938 [Abstract] [Full Text]  
• Hyun, C L, Lee, H E, Kim, K S, Kim, S-W, Kim, J H, Choe, G, Park, S Y (2008). The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J. Clin. Pathol. 61: 317-321 [Abstract] [Full Text]